Hata Yujiro S 4

What Happened Yujiro S. Hata, a director of Enanta Pharmaceuticals, was granted a derivative award covering 20,000 shares on March 11, 2026. The Form 4 reports the acquisition price as $0.00 and classifies the transaction as an award/grant of a derivative security (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-13 (filed within the typical 2-business-day window).
• Transaction type/code: A (award/grant or other acquisition of derivative securities).
• Shares/units granted: 20,000 (reported acquisition value $0.00 on the Form 4).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option becomes exercisable in substantially equal monthly installments over one year beginning March 11, 2026, with the final monthly installment vesting no later than the nearest Nasdaq trading day before Enanta’s 2027 annual meeting.

Context This was a grant of a derivative award (an option or similar right) rather than a cash purchase or sale. The $0.00 reported on the Form 4 reflects the award grant reporting; the exercise price, if any, and any future taxable or cash events (exercise, sale, or tax withholding) are not detailed here. Grants to directors are common as part of compensation and do not by themselves indicate intent to buy or sell company stock.